Published in Nat Rev Drug Discov on November 16, 2015
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Safety Study of CALAA-01 to Treat Solid Tumor Cancers | NCT00689065
Study With Atu027 in Patients With Advanced Solid Cancer | NCT00938574
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery | NCT01591356
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation | NCT00802347
TKM 080301 for Primary or Secondary Liver Cancer | NCT01437007
A Study of PNT2258 in Patients With Advanced Solid Tumors | NCT01191775
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01733238
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) | NCT02226965
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. Circ Res (2016) 0.99
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. Oncotarget (2016) 0.79
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine (2016) 0.78
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Proc Natl Acad Sci U S A (2016) 0.76
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano (2017) 0.76
Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics (2017) 0.75
The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. Int J Mol Sci (2017) 0.75
Targeting SR-BI for Cancer Diagnostics, Imaging and Therapy. Front Pharmacol (2016) 0.75
The long noncoding RNA Tug1 connects metabolic changes with kidney disease in podocytes. J Clin Invest (2016) 0.75
Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int J Nanomedicine (2017) 0.75
Efficient tuning of siRNA dose response by combining mixed polymer nanocarriers with simple kinetic modeling. Acta Biomater (2017) 0.75
Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload. Oxid Med Cell Longev (2017) 0.75
Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery? Genes (Basel) (2017) 0.75
Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation. Int J Nanomedicine (2017) 0.75
Transferrin-Dressed Virus-like Ternary Nanoparticles with Aggregation-Induced Emission for Targeted Delivery and Rapid Cytosolic Release of siRNA. ACS Appl Mater Interfaces (2017) 0.75
MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents. Curr Pathobiol Rep (2017) 0.75
Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett (2017) 0.75
Molecular dynamics study on the mechanism of polynucleotide encapsulation by chitosan. Sci Rep (2017) 0.75
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm (2009) 3.49
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res (2006) 3.22
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell (2014) 2.90
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature (2014) 2.70
A status report on RNAi therapeutics. Silence (2010) 2.18
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest (2009) 2.13
Chemical modification of siRNAs for in vivo use. Oligonucleotides (2008) 2.03
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol (2009) 1.86
Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci (2013) 1.81
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev (2012) 1.66
The CRISPR craze. Science (2013) 1.63
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng (2008) 1.60
Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc (2012) 1.57
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov (2015) 1.56
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A (2012) 1.52
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng (2007) 1.36
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med (2007) 1.34
Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev (2012) 1.34
Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol (1999) 1.33
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol (2012) 1.32
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc (2014) 1.31
Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol (2006) 1.27
RNAi therapies: drugging the undruggable. Sci Transl Med (2014) 1.26
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano (2014) 1.23
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun (2014) 1.19
Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev (2012) 1.15
Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci U S A (2014) 1.13
The dicey role of Dicer: implications for RNAi therapy. Cancer Res (2010) 1.13
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther (2013) 1.08
Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides (2008) 1.08
Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther (2014) 1.05
Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem (2015) 1.04
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs (2013) 1.02
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther (2012) 1.02
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res (2012) 1.00
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A (2014) 0.99
Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest (2010) 0.97
In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials (2012) 0.95
Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov (2014) 0.95
Long-distance communication between laryngeal carcinoma cells. PLoS One (2014) 0.94
Gene silencing by double-stranded RNA (Nobel Lecture). Angew Chem Int Ed Engl (2007) 0.94
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res (2014) 0.92
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther (2011) 0.92
Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther (2008) 0.92
First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol (2014) 0.91
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.91
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol (2010) 0.90
Antisense therapeutics in oncology: current status. Onco Targets Ther (2014) 0.89
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget (2015) 0.89
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther (2011) 0.86
Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int J Nanomedicine (2015) 0.84
Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication. Cancer Res (2013) 0.82
Tissue-specific gene silencing monitored in circulating RNA. RNA (2013) 0.81
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv Transl Res (2014) 0.81
Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model. Nanomedicine (2015) 0.80
Prognostic significance of deregulated dicer expression in breast cancer. PLoS One (2013) 0.80
Therapeutic oligonucleotides: the road not taken. Clin Cancer Res (2011) 0.79
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell Mol Life Sci (2013) 0.79
Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance. Mol Pharm (2012) 0.79
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates. J Control Release (2014) 0.78
Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine (Lond) (2013) 0.78